Adeno-Associated Virus Vectors for Hemophilia Gene Therapy

Time: 4:10 pm
day: Day One

Details:

• rAAV manufacturing capacity for clinical and nonclinical research
• Vector quality and research outcomes
• Clinical benefit and persistence and safety

Speakers: